Recent Advances in Therapeutic Drug Monitoring and Clinical Toxicology

This book gives an overview of therapeutic drug monitoring (TDM) and its clinical application. It also highlights recent advances in toxicological studies, as they relate to therapeutic drug monitoring. This is one of the few books available on the market that covers TDM. Therapeutic drug monitoring (TDM) is a clinical decision-making tool that enables dosage regimen adjustments based on clinical and laboratory measurements. TDM not only involves the measuring of drug concentrations but also interpretation of the results. There is a strong correlation between drug concentrations in body fluids and outcome than between dose and outcome. The chapters include coverage of analytical techniques, pharmacokinetics, therapeutic indices, artificial intelligence and recent advances in toxicological studies. The book fills a gap in published literature and provides reliable information on; Analytical techniques in TDM and clinical toxicology TDM and pharmacokinetic studies TDM of drugs with narrow therapeutic indices Artificial intelligence in TDM and clinical toxicology Future directions and challenges Foreword Preface Contents About the Editors Contributors 1: Therapeutic and Toxic Concentrations of Drugs in Biological Matrices 1.1 Introduction 1.2 Therapeutic Drug Monitoring 1.3 Biological Matrices 1.3.1 Blood 1.3.2 Urine 1.3.3 Saliva 1.3.4 Cerebrospinal Fluid (CSF) 1.3.5 Hair 1.4 Therapeutic Concentration of Drugs 1.5 Toxic Concentration of Drugs 1.6 Conclusion References 2: Analytical Techniques for Therapeutic Drug Monitoring and Clinical Toxicology 2.1 Introduction 2.2 Immunoassays 2.3 Electrophoresis 2.4 Biosensors 2.5 Conventional HPLC and Emerging UHPLC Techniques 2.6 Gas Chromatography (GC) 2.7 Conclusion and Outlook References 3: Plasma Therapeutic Drug Monitoring and Clinical Toxicology 3.1 Overview of Therapeutic Drug Monitoring (TDM) 3.1.1 Assumptions 3.1.2 Process of Therapeutic Drug Monitoring 3.2 Indications for Measuring Plasma Concentrations 3.2.1 Avoiding or Diagnosing Toxicity 3.2.2 Diagnosing Undertreatment and Monitoring Patient Adherence 3.2.3 Prophylaxis 3.2.4 Drug Interactions and Termination of Treatment 3.3 Proper Use of Measurements 3.3.1 Timing of Blood Samples 3.3.2 Type of Sample Used 3.3.3 Measurement Technique 3.3.4 Individualization of Results 3.4 Individualizing Therapy 3.4.1 Formulation and Diet 3.4.2 Pharmacokinetics: Ion Trapping 3.4.3 Pathologic Disease States 3.4.4 Cytochrome P450 Enzymes 3.4.5 Age 3.5 Serum Versus Plasma Monitoring 3.5.1 Drugs Requiring Monitoring: Digoxin 3.5.2 Drugs Requiring Monitoring: Phenytoin 3.6 Renal Clearance and Metabolism in Therapeutic Drug Monitoring 3.6.1 Critically Ill Patients 3.6.2 Geriatric Patients 3.6.3 Pediatric Patients 3.6.4 Acute or Chronic Renal Failure Patients 3.7 Role of Cytochrome P450 Systems in Liver Clearance and Metabolism 3.7.1 Acetaminophen 3.7.2 Rifampin 3.7.3 Erythromycin 3.8 Antiretrovirals and Glucose in Therapeutic Drug Monitoring 3.8.1 The Role and Influence of Glucose in Therapeutic Drug Monitoring 3.8.2 Therapeutic Drug Monitoring of Antiretroviral Drugs 3.9 Conclusion References 4: Dried Blood Spots in Therapeutic Drug Monitoring and Toxicology 4.1 Introduction 4.2 Therapeutic Drug Monitoring (TDM) 4.2.1 DBS in PK Monitoring 4.2.2 Factors to Consider in PK Studies Using DBS Sampling 4.2.3 Toxicology 4.2.3.1 Toxicokinetics 4.2.3.2 Forensic Toxicology 4.2.3.3 Screening for Environmental Contaminants 4.3 The Hematocrit Factor 4.3.1 Holistic Analysis of Volumetrically Spotted DBS 4.3.2 Use of DPS in Place of DBS 4.3.3 Use of Special Filter Substrates 4.3.4 Use of Hematocrit Calibrators 4.3.5 Estimation or Prediction of Hematocrit 4.4 General Steps in DBS Sampling 4.4.1 Selection of Filter Material 4.4.2 Collection of Specimen 4.4.3 Drying of Spotted Cards 4.4.4 Packaging of DBS for Storage and Transport 4.4.5 Extraction and Analysis of Analyte 4.4.6 Validation of DBS-Based Analytical Processes 4.5 Recent Innovative DBS Sampling Alternatives 4.6 High-Throughput Application of DBS Sampling 4.7 Conclusion and Future Perspectives References 5: The Role of Artificial Intelligence in Therapeutic Drug Monitoring and Clinical Toxicity 5.1 Introduction 5.2 AI Terms 5.2.1 Machine Learning (ML) 5.2.2 Deep Learning (DL) 5.2.3 Artificial Neural Network (ANN) 5.3 Implementing AI in Drug Design: Early Stages 5.4 Essentials for Implementing AI in Drug Discovery 5.4.1 Data Describing the System 5.4.2 Integration of Data 5.4.3 System Stability 5.4.4 Dimension and Interdependency 5.4.5 Field Knowledge 5.5 AI or Ligand Discovery: Which One Is Critical in Drug Discovery? 5.6 AI in Drug Monitoring: Gathering Medical Big Data 5.7 Pipeline for Disease Monitoring 5.7.1 Target Selection, Validation 5.7.2 Design, Optimization of Drug Design 5.7.3 Clinical Studies (Virtual) 5.8 AI in Pharmacovigilance 5.9 AI in Toxicity 5.10 Structural Toxicity for Endpoints 5.10.1 Toxicity for Multiple-Time Point Assays 5.11 AI for Drug Safety: Recent Advances and Post-Market Surveillance 5.12 Illusions and Reality of AI in Drug Design 5.13 Future of AI in Drug Design 5.14 Conclusions References 6: Therapeutic Drug Monitoring and Optimal Pharmacotherapy with Medicines of Narrow Therapeutic Index 6.1 Background 6.2 Therapeutic Drug Monitoring 6.3 Medicines That Are Known to Require Therapeutic Drug Monitoring 6.4 Medication Therapy That Requires TDM for Optimal Outcomes 6.5 Guidelines for Sample Collection 6.6 Timing of Plasma Sample for TDM 6.7 Request for Therapeutic Drug Monitoring 6.8 Therapeutic Drug Monitoring and Interpretation of Results 6.9 Medications That May Benefit from Therapeutic Drug Monitoring 6.10 Techniques for Measurement of Therapeutic Drug Monitoring 6.11 Practical Use of Therapeutic Drug Monitoring References 7: Therapeutic Drug Monitoring (TDM) and Toxicological Studies in Alternative Biological Matrices 7.1 Introduction 7.2 Therapeutic Drug Monitoring (TDM) 7.2.1 Purpose of Therapeutic Drug Monitoring (TDM) 7.2.2 TDM: Estimating Plasma Drug Concentration 7.2.3 TDM Analytical Issues 7.2.4 Practical Issues in TDM 7.2.5 TDM’s Translational Challenges 7.2.6 Recent Advances in TDM Practice 7.2.6.1 Chromatographic Methods 7.2.6.2 Immunoassays 7.2.6.3 Biosensors 7.2.6.4 Biochips 7.3 Science of Toxicology 7.3.1 Toxicology: Biological Sampling and Use of Different Analytical Techniques 7.3.1.1 Reasons for Testing 7.3.1.2 Pharmacologic Reasons 7.3.1.3 Pharmacokinetic Reasons 7.3.1.4 Availability of Specimens 7.3.1.5 Ease of Collection 7.4 Alternative Matrices in Toxicology 7.5 Different Approaches in Various Biological Matrices, with an Emphasis on Toxicology 7.5.1 Microextraction Techniques in Different Biological Matrices 7.5.2 Other Green Extraction Technique Application 7.5.3 Applications of Mass Spectrometry Techniques in Alternative Biological Matrices 7.6 Artificial Intelligence (AI) in Toxicity and Drug Discovery 7.7 Promises and Pitfalls of Alternative Matrices 7.8 Artificial Intelligence (AI) in Toxicology and TDM 7.8.1 Artificial Intelligence for Clinical Toxicity and Patient Safety 7.8.2 Artificial Intelligence (AI) in the Prediction of Adverse Drug Reaction (ADR) and a Case Study 7.9 Importance and Future Perspective of TDM 7.10 Challenges Faced in Managing Patient Health Data 7.11 Conclusions References 8: Analyzing Data from Therapeutic Drug Monitoring, Pharmacokinetics, and Clinical Toxicology Studies 8.1 Introduction 8.1.1 Software Setup 8.2 Endpoints 8.3 Types of Data 8.4 Data Handling 8.5 Pharmacokinetics 8.5.1 Single-Dose PK Parameters 8.5.1.1 Cmax and tmax 8.5.1.2 AUCt 8.5.1.3 λ and t1/2 8.5.1.4 AUC∞ 8.5.1.5 CL/F and Vd/F 8.5.2 Steady-State PK Parameters 8.5.2.1 Cav,SS and CSS 8.5.2.2 Ctrough and Cmax,SS 8.6 Pharmacodynamics 8.6.1 PK/PD 8.7 Descriptive and Inferential Statistics 8.7.1 Statistical Hypothesis Testing 8.7.1.1 Type I Error 8.7.1.2 Type II Error 8.7.1.3 Significance Testing and p-Value 8.7.2 Confidence Interval (CI) 8.8 Sample Size and Power 8.9 Analysis Methods 8.9.1 Categorical Endpoints/Comparison of Proportions 8.9.1.1 Chi-Square Test 8.9.1.2 Fisher’s Exact Test 8.9.1.3 McNemar Test 8.9.1.4 Logistic Regression 8.9.2 Continuous Endpoints/Comparison of Means 8.9.2.1 One-Sample T-Test 8.9.2.2 One-Sample Wilcoxon Test 8.9.2.3 Independent T-Test 8.9.2.4 Wilcoxon Rank Sum (Mann-Whitney U) Test 8.9.2.5 Paired T-Test 8.9.2.6 Wilcoxon Signed Rank Test 8.9.2.7 Linear Regression 8.9.2.8 Analysis of Variance (ANOVA) 8.9.2.9 Kruskal-Wallis Test References 9: Reducing Toxicity in Critically Ill Patients by Using Therapeutic Drug Monitoring 9.1 Introduction 9.1.1 Critically Ill Patients 9.1.2 Therapeutic Drug Monitoring 9.2 Antimicrobial Agents 9.2.1 General Pharmacokinetics (PK)/Pharmacodynamics (PD) Targets 9.2.2 Antibacterial Agents/Antibiotics 9.2.2.1 Aminoglycosides PK/PD Targets Dose Adjustment Strategies Bioanalytical Assay 9.2.2.2 ß-Lactams PK/PD Targets Dose Adjustment Strategies Bioanalytical Assay 9.2.2.3 Fluoroquinolones PK/PD Targets Dose Adjustment Strategies Bioanalytical Assay 9.2.2.4 Vancomycin PK/PD Targets Dose Adjustment Strategies Bioanalytical Assay 9.2.2.5 Linezolid PK/PD Targets Dose Adjustment Strategies Bioanalytical Assay 9.2.3 Antifungal Agents 9.2.3.1 Fluconazole PK/PD Targets Dose Adjustment Strategies Bioanalytical Assay 9.2.3.2 Flucytosine PK/PD Targets Dose Adjustment Strategies Bioanalytical Assay 9.2.4 Antiviral Agents 9.2.4.1 Acyclovir/Valacyclovir PK/PD Targets Dose Adjustment Strategies Bioanalytical Assay 9.2.4.2 Ribavirin PK/PD Targets Dose Adjustment Strategies Bioanalytical Assay 9.3 Anticoagulant Agents 9.4 Sedative and Analgesic Agents 9.5 Vasopressors and Inotropic Agents 9.6 Neuromuscular Blocking Agents 9.7 Conclusion References 10: Quality Assurance of Samples for Therapeutic Drug Monitoring and Clinical Toxicology 10.1 Introduction 10.2 Sample Acquisition, Handling, and Storage 10.3 Sample Preparation and Validation Techniques 10.4 Sample Testing or Analysis 10.5 Automation of Testing Laboratory 10.6 Conclusion and Outlook References 11: Therapeutic Drug Monitoring and Toxicology of Anticancer Drugs 11.1 Introduction 11.1.1 Individualization of Drug Therapy 11.2 Therapeutic Drug Monitoring (TDM) 11.2.1 Criteria for TDM 11.2.2 Features of Drug for Apt Candidature for TDM 11.3 Therapeutic Drug Monitoring for Various Drugs 11.4 Importance of Clinical Pharmacokinetic Parameters in Context to Anticancer Agents 11.5 Methods for Individualization of Drug Therapy 11.6 Therapeutic Drug Monitoring Approach of Anticancer Drug 11.6.1 Importance of TDM in the Management of Cancer 11.6.2 Limitations of TDM for Anticancer Drugs 11.7 Beneficial Aspects of TDM for Cancer Therapy 11.7.1 Carboplatin 11.7.2 Methotrexate 11.7.3 13-Cis-Retinoic Acid 11.7.4 Busulfan 11.7.5 5-Fluorouracil (5-FU) 11.7.6 Mitotane 11.7.7 Tamoxifen 11.7.8 Imatinib 11.7.9 Pazopanib 11.8 Final Remark References 12: Therapeutic Drug Monitoring and Toxicology of Immunosuppressant 12.1 Introduction 12.2 Therapeutic Drug Monitoring of Immunosuppressants 12.3 Classification of Immunosuppressant Drugs 12.3.1 Calcineurin Inhibitors: (Cyclosporine and Tacrolimus) 12.3.2 Antiproliferative Agents: (Mycophenolate Mofetil, Azathioprine, Methotrexate, Cyclophosphamide, and Chlorambucil) 12.3.3 mTOR Inhibitors: (Sirolimus and Everolimus) 12.4 Adverse Effects and Toxicity of Newer Immunosuppressant Drugs 12.5 Immunosuppressant Drug Interactions 12.6 Toxicity Related to Immunosuppressant Agents 12.7 The Toxicities Related to Various Immunosuppressants Are as Follows 12.8 Conclusion and Future Perspective References 13: Therapeutic Drug Monitoring and Toxicology: Relevance of Measuring Metabolites 13.1 Brief Overview of Therapeutic Drug Monitoring (TDM) 13.1.1 Brief History of TDM 13.1.2 Importance of TDM in Clinical Settings 13.1.3 Current Clinical Practice Gaps Associated with Measuring Parent Compounds 13.2 Metabolites and Drug Monitoring 13.2.1 Importance of Metabolite Measurements in TDM 13.2.2 Metabolite Measurement in TDM 13.2.3 Drug Metabolism and Toxicity 13.2.3.1 An Overview of Mechanisms Involved in the Bioactivation of Drugs to Toxic Metabolites 13.3 Polymorphism in Drug Metabolism 13.3.1 Polymorphism in Expression of CYPs 13.3.1.1 CYP1A1 13.3.1.2 CYP1A2 13.3.1.3 CYP2C9 13.3.1.4 CYP2C19 13.3.1.5 CYP2D6 13.3.1.6 CYP3A4/5 13.3.2 Uridine Diphosphate-Glucuronosyltransferases (UGTs) 13.3.3 Other Polymorphisms in Drug Metabolism 13.3.3.1 TPMT and NUDT15 13.3.3.2 Vitamin K Epoxide Reductase Complex Subunit 1 (VKORC1) 13.4 Pro-drugs, TDM, and Metabolite Measurement 13.4.1 Toxicity of Metabolites of Pro-drugs 13.5 Conclusions and Future Directions References 14: Recent Advances in Nanosensors for Therapeutic Drug Monitoring (TDM) 14.1 Traditional TDM and the Need for Nanosensors 14.2 Traditional TDM Practice Versus Recent Advances 14.3 Definition of Nanomaterials 14.4 Definition of Nanosensors 14.5 Current Nanosensor Techniques for TDM 14.6 Nanosensors for Clinical Use 14.6.1 Nanosensor for Gemcitabine 14.6.2 Nanosensors for Specific Antibiotics 14.6.2.1 Nanosensor for the Antifungal Flucytosine 14.6.2.2 Nanosensor for Linezolid 14.6.2.3 Nanosensor for Amikacin 14.6.2.4 Nanosensor for Gentamicin 14.6.3 Nanosensors for Digoxin 14.6.4 Nanosensors for Blood-Thinning Agents 14.6.4.1 Nanosensors for Warfarin 14.6.4.2 Nanosensor for Heparin 14.6.4.3 Nanosensor for Aspirin 14.6.5 Nanosensor for Tramadol 14.6.6 Nanosensor for Sulfasalazine 14.6.7 Nanosensors for Theophylline 14.6.8 Nanosensor for Levothyroxine 14.6.9 Nanosensor for Lithium 14.6.10 Nanosensors for Anticonvulsants 14.6.10.1 Nanosensor for Carbamazepine 14.6.10.2 Nanosensors for Phenobarbital 14.6.10.3 Nanosensor for Valproic Acid 14.6.10.4 Nanosensor for Phenytoin References 15: Organ Toxicity by Immunosuppressive Drugs in Solid Organ Transplantation 15.1 Introduction 15.1.1 Historical Account of Immunosuppressive Drugs in Clinical Organ Transplantation 15.2 Immunosuppressant-Induced Organ Toxicity After Solid Organ Transplantation 15.2.1 Immunosuppressant-Induced Nephrotoxicity 15.2.2 Immunosuppressant-Induced Neurotoxicity 15.2.3 Immunosuppressant-Induced Cardiotoxicity 15.2.4 Immunosuppressant-Induced Pulmonary Toxicity 15.2.5 Immunosuppressant-Induced Gastrointestinal Toxicity 15.2.6 Immunosuppressant-Induced Hepatotoxicity 15.3 Reducing the Burden of Immunosuppression After Solid Organ Transplantation References 16: Artificial Intelligence-Based Techniques to Assess Drug Toxicity in Drug-Induced Liver Injury (DILI) Disease 16.1 Introduction 16.2 Etiology 16.3 LiverTox 16.3.1 Phenotype of DILI 16.3.2 Classification of DILI Drugs 16.4 Liver Causality Assessment Tools 16.5 Computational Pathology for DILI Injury Assessment 16.6 Liver Toxicity and Fatty Liver 16.7 Artificial Intelligence in DILI Pattern Detection 16.7.1 AuML for DILI Pattern Detection 16.7.2 Deep Learning Model for DILI 16.8 Conclusion Bibliography 17: Drug Dose and Therapy Individualization 17.1 Introduction to Pharmacodynamics and Pharmacokinetics 17.2 Influence of Pharmacodynamics and Pharmacokinetics on Dosing 17.2.1 Drug Dosing and Weight 17.2.2 Dosing Algorithm as Population Based 17.3 Examples of Commonly Individualized Medications and Their Pharmacology 17.3.1 Warfarin 17.3.2 Glipizide 17.3.3 Codeine 17.3.4 Clozapine 17.4 Drug Dosing in Patients with Comorbidities 17.4.1 Involvement of CYP450 in Drug Metabolism 17.4.2 Infection 17.4.3 Obesity 17.4.4 Renal Insufficiency 17.5 Implications of Incorrect Drug Dosing 17.5.1 Drugs with a Significant Risk of Overdose: Opioids 17.5.2 Drugs with a Significant Risk of Overdose: OTC Medications 17.5.3 Overdose Prevention as Part of Drug Individualization 17.6 Conclusion References 18: Models for Drug Individualization: Patient to Population Level 18.1 Historical Perspectives on Therapy Individualization 18.2 Patient Populations and Drug Individualization 18.2.1 Race and Ethnicity 18.2.2 Age 18.2.3 Sex 18.2.4 Other Considerations 18.3 Models for Drug Individualization 18.3.1 Current Practices for Drug-Resistant Problems 18.3.2 Physiologically Based Pharmacokinetic (PBPK) Modeling 18.3.3 Pharmacogenetics 18.4 Challenges to Individualization 18.4.1 Body Mass and Body Surface Area Dosing 18.4.2 PK/PD and PBPk Modeling 18.4.3 TDM 18.5 Conclusion References 19: Toxicity Evaluation of Nanomedicine 19.1 Introduction 19.2 Breakthrough Success of Nanomedicine 19.3 Benefit-Risk Assessment of Nanotherapeutics 19.4 Toxicity Profile of Nanomedicine 19.4.1 Hepatotoxicity 19.4.2 Reproductive and Developmental Toxicity 19.4.3 Pulmonary Toxicity 19.4.4 Nephrotoxicity 19.4.5 Neurotoxicity 19.4.6 Cardiotoxicity 19.4.7 Genotoxicity 19.5 Insights Into Mechanisms of Toxicity 19.5.1 Oxidative Stress 19.5.2 Inflammation 19.5.3 Apoptosis 19.5.4 Lysosomal Dysfunction and Autophagy 19.5.5 Necrosis 19.5.6 DNA Damage 19.6 Evaluation Techniques of Nanomedicine Toxicity 19.6.1 In Vitro Approaches for Toxicity Evaluation 19.6.2 In Vivo Approaches for Toxicity Evaluation 19.6.3 Sensor-Based Techniques 19.6.4 Omics Techniques 19.7 Conclusion References 20: Biochemical Indices of Drug Toxicity 20.1 Introduction 20.2 Kidneys 20.2.1 Serum Creatinine and Urea 20.2.2 The Glomerular Filtration Rate (GFR) and Clearance 20.2.3 Blood Cystatin C 20.2.4 Fibrinogen 20.2.5 Kidney Injury Molecule-1 20.2.6 Neutrophil Gelatinase-Associated Lipocalin 20.2.7 N-Acetyl-beta- glucosaminidase 20.2.8 Beta-2-Microglobulin 20.2.9 Electrolytes 20.2.10 Sodium 20.2.11 Potassium 20.2.12 Chloride 20.2.13 Calcium 20.2.14 Magnesium 20.2.15 Phosphates 20.2.16 Iron 20.3 Liver 20.3.1 Aminotransferases 20.3.2 Cholestatic Enzymes 20.3.3 Alkaline Phosphatase 20.3.4 Gamma-Glutamyl Transpeptidase 20.3.5 Blood Bilirubin 20.3.6 Glutamate Dehydrogenase 20.3.7 Sorbitol Dehydrogenase 20.3.8 Plasma Proteins 20.3.9 Other Enzymes of Toxicological Relevance 20.3.10 Other Non-enzymes of Toxicological Relevance 20.3.10.1 Triglycerides 20.3.10.2 Cholesterol 20.3.10.3 Bile Acids 20.3.10.4 Glucose 20.3.10.5 Cytokines 20.4 Muscle 20.5 Cardiac 20.6 Recent Developments and Future Perspectives 20.7 Conclusion References 21: Therapeutic Drug Monitoring and Clinical Toxicology: Challenges and Future Directions 21.1 Introduction 21.2 Reasons for TDM 21.3 Challenges with TDM 21.3.1 Drug in Circulation May Not Correspond to Amount at Site of Action 21.3.2 Low Sensitivity of Some of the Assays Used in TDM 21.3.3 Difficulties in Sampling at the Right Time 21.3.4 Inability to Assay Some Active Metabolites of Drug 21.3.5 Inaccuracies in Detecting Medication Compliance 21.3.6 TDM Is Expensive 21.3.7 Challenges with Sampling and Sample Handling Before Analysis 21.4 Future Directions 21.4.1 Alternate Sampling Matrices 21.4.2 Individualized Therapeutic Concentration 21.4.3 Appropriate Clinical Interpretation of TDM Results 21.4.4 Merging Target Concentration Intervention (TCI) with TDM 21.4.5 Computer-Assisted TDM 21.5 Conclusion References Index This book gives an overview of therapeutic drug monitoring (TDM) and its clinical application. It also highlights recent advances in toxicological studies, as they relate to therapeutic drug monitoring. This is one of the few books available on the market that covers TDM. Therapeutic drug monitoring (TDM) is a clinical decision-making tool that enables dosage regimen adjustments based on clinical and laboratory measurements. TDM not only involves the measuring of drug concentrations but also interpretation of the results. There is a strong correlation between drug concentrations in body fluids and outcome than between dose and outcome. The chapters include coverage of analytical techniques, pharmacokinetics, therapeutic indices, artificial intelligence and recent advances in toxicological studies. The book fills a gap in published literature and provides reliable information on; 1. Analytical techniques in TDM and clinical toxicology 2. TDM and pharmacokinetic studies 3. TDM of drugs with narrow therapeutic indices 4. Artificial intelligence in TDM and clinical toxicology 5. Future directions and challenges